Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease

I T GILMORE AND R P H THOMPSON†

From the Gastrointestinal Laboratory, Rayne Institute, St Thomas' Hospital, London

SUMMARY The apparent plasmas clearances of tracer amounts of radiolabelled cholic acid given orally or intravenously were compared in 14 control subjects and 20 patients with chronic liver disease. The clearance after oral administration was the more sensitive in detecting chronic liver disease and correlated better with the fasting levels of endogenous serum bile acid. This agrees with the predicted effects on clearance of hepatocellular damage and portal-systemic shunting of blood after the two routes of administration. The estimated hepatic extraction ratio, calculated from the ratio of the oral and intravenous clearances, was 0·77±0·02 (mean±SEM) in control subjects, 0·64±0·03 in patients with anicteric chronic liver disease, and 0·46±0·05 in those with icteric chronic liver disease.

The concentration of endogenous bile acids in blood is a useful marker of liver disease and of comparable sensitivity to levels of α-glutamyl transpeptidase or aspartate aminotransferase. Paradoxically, the disappearance rate from plasma of intravenously administered radiolabelled bile acids is not as sensitive but this has not been satisfactorily explained. One possibility is the difference for bile acids between direct administration into the vascular compartment and absorption from the intestine into blood; in the former, elimination from plasma is highly dependent on liver blood flow, whereas in the latter all absorbed bile acid is subject to first-pass extraction and elimination by the normal liver, irrespective of liver blood flow, before reaching peripheral blood. This suggests that the apparent plasma clearance of radiolabelled bile acid given orally would be more sensitive to liver damage than that of bile acid given intravenously, and would correlate more closely with endogenous serum bile acid concentrations. We set out to test this hypothesis, and to evaluate the use of the ratio of the intravenous and oral clearances for measuring hepatic extraction.

Methods

All studies were approved by the Ethical Committee of the hospital and by the DHSS Isotopes Advisory Committee.

*Some of this work was presented to the British Society of Gastroenterology, Warwick, 1978.
†Correspondence to R P H Thompson.

Received for publication 7 August 1979
Table 1  Diagnosis and biochemical findings in 20 patients with chronic liver disease undergoing combined oral/intravenous cholic acid clearance estimations

<table>
<thead>
<tr>
<th>Patients</th>
<th>No.</th>
<th>M:F</th>
<th>Age*</th>
<th>Billirubin*</th>
<th>Alk phos*</th>
<th>SGOT*</th>
<th>Alb*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control subjects</td>
<td>14</td>
<td>8:6</td>
<td>54 (21-78)</td>
<td>&lt;17</td>
<td>&lt;14</td>
<td>&lt;50</td>
<td>&gt;40</td>
</tr>
<tr>
<td>Active chronic hepatitis (8 cirrhotic)</td>
<td>11</td>
<td>2:9</td>
<td>42 (24-70)</td>
<td>38</td>
<td>12</td>
<td>310</td>
<td>39</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
<td>8</td>
<td>8:0</td>
<td>54 (43-67)</td>
<td>26</td>
<td>15</td>
<td>115</td>
<td>39</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>1</td>
<td>F</td>
<td>68 (6-74)</td>
<td>8</td>
<td>17</td>
<td>55</td>
<td>42</td>
</tr>
<tr>
<td>Icteric chronic liver disease (ACLD)</td>
<td>16</td>
<td>8:8</td>
<td>44 (24-70)</td>
<td>13</td>
<td>12</td>
<td>120</td>
<td>40</td>
</tr>
<tr>
<td>Icteric chronic liver disease (ICLD)</td>
<td>4</td>
<td>3:1</td>
<td>50 (27-63)</td>
<td>100</td>
<td>20</td>
<td>620</td>
<td>37</td>
</tr>
</tbody>
</table>

*Mean and range.

taneously using $^{14}$C and $^3$H labelled cholic acid. No difference was noted between the two methods in the control subjects; the simultaneous dual-isotope method was used for all the patients with chronic liver disease.

Subjects were studied at rest after an overnight fast. After an initial blood sample, 5 $\mu$Ci $^{14}$C-cholic acid was given intravenously and heparinised blood samples drawn from an indwelling 19G needle in the other arm at 2, 4, 6, 8, 10, 12, 15, 20, 25, and 30 minutes. At this time 15 $\mu$Ci $^3$H-cholic acid made up to 50 ml with water was given by mouth, and blood samples drawn at 10 minute intervals up to 150 minutes.

Samples were centrifuged, 1 ml plasma added to 10 ml liquid scintillator (NE 260, Nuclear Enterprises, Edinburgh), and counted in a liquid scintillation counter (NE 8132, Nuclear Enterprises) for 30 to 60 minutes until three consecutive counts were in agreement. $^3$H and $^{14}$C counts were separated by adjusting the higher energy channel to exclude all $^3$H counts and the lower energy channel to include about 20% of $^{14}$C counts; quench correction was performed by the external standard channels ratio method.

**ERUM BILE ACID ESTIMATION**
This was performed using a 3α-hydroxysteroid dehydrogenase assay after extraction on Amberlite XAD-7 (a gift from Rohm and Haas (UK), Croydon) as previously described.6 Concentrations were measured on fasting samples in all the control subjects and in 19 of the patients with chronic liver disease. All control subjects fell within our normal range of 0.5-12.5 $\mu$mol.1$^{-1}$.

**CALCULATION OF RESULTS**
For both oral and intravenous administration, plasma clearance rate was calculated from the equation:

\[
\text{Clearance} = \frac{\text{Dose}}{[\text{AUC}]} \quad \text{Eq. 1}
\]

where [AUC]$^0_{\text{in}}$ is the area under the plasma concentration—time curve extrapolated to times zero and infinity, calculated using the trapezoid rule. The initial distribution volume (V) after intravenous injection was calculated from:

\[
V = \frac{\text{Dose}}{\text{concn at } t=0} \quad \text{Eq. 2}
\]

Hepatic extraction ratio (E) was calculated indirectly from the relationship:

\[
1-E = \frac{\text{Clearance}_{\text{iv}}}{\text{Clearance}_{\text{oral}}} \quad \text{Eq. 3}
\]

When hepatic extraction, clearance$_{\text{iv}}$ and haematocrit (H) are known, estimated hepatic blood flow (EHBF) may be calculated from the relationship:

\[
\text{EHBF} = \frac{\text{Clearance}_{\text{iv}}}{\text{E. (1-H)}} \quad \text{Eq. 4}
\]

Clearance, distribution volume and estimated hepatic blood flow were standardised for body surface area, calculated from height and weight. The unpaired Student's t test was used to test the significance of observed differences between groups.

**Results**

**CHOLIC ACID CLEARANCE**

**Control subjects**
An example of the oral and intravenous plasma disappearance curves is shown in Fig. 1. After intravenous injection, cholic acid clearance was $271 \pm 15 \text{ml.min}^{-1}\cdot\text{m}^{-2}$ (mean $\pm$ SEM), with an initial distribution volume of $1879 \pm 54 \text{ml.m}^{-2}$, m$^{-2}$. Apparent plasma clearance after oral administration was $1248 \pm 104 \text{ml.min}^{-1}\cdot\text{m}^{-2}$. The estimated hepatic
Plasma clearance of oral and intravenous cholic acid

Patients with chronic liver disease
The plasma clearances, extraction ratios and distribution volumes are shown in Table 2. In all groups, the oral clearance was more severely reduced than the intravenous clearance; for instance, in the group with alcoholic cirrhosis the intravenous clearance was maintained within normal limits, whereas the oral clearance was reduced to less than 50%. The distribution volume was greater in all groups of patients with chronic liver disease than in controls, and was also significantly greater in the icteric than the anicteric group.

Fasting serum bile acid concentrations
Endogenous fasting concentrations of bile acids were abnormal in the four icteric patients and in all but six of those with anicteric chronic liver disease (Fig. 2). The sensitivities of bile acid clearance and fasting serum bile acid concentration for the detection of anicteric chronic liver disease are compared in Figs. 3 and 4. There was a stronger correlation between serum bile acids and oral clearance than between serum bile acids and intravenous clearance, and when results for each were divided into normal

Table 2  Clearances and distribution of 14C-cholic acid in patients with chronic liver disease

<table>
<thead>
<tr>
<th>Patients</th>
<th>Volume of distribution (ml.m⁻²)</th>
<th>Intravenous clearance (ml.min⁻¹.m⁻²)</th>
<th>Oral clearance (ml.min⁻¹.m⁻²)</th>
<th>Extraction ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (14)</td>
<td>1879 ± 54</td>
<td>271 ± 15</td>
<td>1248 ± 104</td>
<td>0.77 ± 0.02</td>
</tr>
<tr>
<td>Active chronic hepatitis (11)</td>
<td>2316 ± 195</td>
<td>173 ± 23</td>
<td>556 ± 105§</td>
<td>0.62 ± 0.05§</td>
</tr>
<tr>
<td>Alcoholic cirrhosis (8)</td>
<td>2428 ± 148§</td>
<td>220 ± 18</td>
<td>550 ± 93§</td>
<td>0.58 ± 0.04§</td>
</tr>
<tr>
<td>Primary biliary cirrhosis (1)</td>
<td>2010</td>
<td>233</td>
<td>696</td>
<td>0.67</td>
</tr>
<tr>
<td>Anicteric chronic liver disease (ACLD) (16)</td>
<td>2221 ± 134*</td>
<td>219 ± 19*</td>
<td>652 ± 65§</td>
<td>0.64 ± 0.03§</td>
</tr>
<tr>
<td>Icteric chronic liver disease (ICLD) (4)</td>
<td>2842 ± 60§</td>
<td>99 ± 22§</td>
<td>194 ± 54§</td>
<td>0.46 ± 0.05§</td>
</tr>
</tbody>
</table>

*P < 0.05
†P < 0.02
‡P < 0.01
§P < 0.001
Fig. 3  A comparison of cholic acid clearance after oral administration and endogenous fasting serum bile acid concentration in anicteric chronic liver disease.

Fig. 4  A comparison of cholic acid clearance after intravenous administration and endogenous fasting serum bile acid concentration in anicteric chronic liver disease.

or abnormal, oral clearance and serum bile acid concentration agreed in 13 of 15 patients, whereas intravenous clearance and serum bile acid concentration did so in only eight.

Discussion

The plasma clearance for cholic acid after intravenous injection in subjects without liver disease, $(271 \pm 15 \text{ ml.min}^{-1}.\text{m}^{-2})$, was slower than that reported for the conjugate glycocholic acid in a comparable group $(377 \pm 33 \text{ ml.min}^{-1}.\text{m}^{-2})$. This agrees with the results of studies in animals in which there was a more rapid hepatic uptake of conjugated than unconjugated bile acids. Furthermore, the initial volume of distribution of $^{14}$C-cholic acid $(1879 \pm 54 \text{ ml.m}^{-2})$ was smaller than that of $^{14}$C-glycocholic acid $(2330 \pm 277 \text{ ml.m}^{-2})$. This has not previously been reported, but is in keeping with data on protein-binding, because the conjugates of cholic acid are less bound to albumin than is unconjugated cholic acid.

The increase in distribution volume of cholic acid observed in patients with chronic liver disease may be due to abnormalities of protein-binding or to increased plasma volume in cirrhosis. Whatever the mechanism, this finding underlines the importance of not relying on half-life times ($T_{1/2}$) or fractional elimination rates ($k_e$) for assessing hepatic uptake; the relationship linking clearance, distribution volume ($V$) and $T_{1/2}$ or $k_e$ (clearance $= V.k_e$ or $V.\ln 2/T_{1/2}$), shows that an increase in $V$ alone results in a prolongation of $T_{1/2}$ without changes in true clearance or hepatic extraction.

The calculation of the extraction ratio from the plasma clearances after intravenous and oral administration assumes complete absorption of the oral dose from the intestine. This has not been confirmed in this study by intestinal intubation, but complete absorption of unconjugated $^3$H chenode-
Plasma clearance of oral and intravenous cholic acid

oxycolic acid from aqueous solution in the jejunum has been demonstrated. Furthermore, the estimated hepatic extraction (0.77 ± 0.02) is in close agreement with recent direct measurements of hepatic extraction of cholic acid by hepatic vein catheterisation, where values of 0.70 and 0.72 were obtained in two subjects without liver disease. It is unlikely that differences in absorption of the orally administered cholic acid would produce the difference in oral clearance between controls and patients with chronic liver disease. Indeed, any malabsorption in liver disease would result in a larger apparent plasma clearance and would therefore tend to obscure any difference from control subjects.

The present work confirms our prediction that measurement of oral clearance of cholic acid would prove more sensitive than that of intravenous clearance in the detection of chronic liver disease. Although it does not provide any evidence on the mechanism, it is likely that it is analogous to the blood concentrations of drugs achieved after oral and intravenous administration. For example, when a substance such as a bile acid with a high hepatic extraction of 80% is given intravenously, a 10% reduction in extraction due to liver disease will cause a proportionate 10% reduction in plasma clearance; however, if the substance is administered orally and fully absorbed, the fraction of the dose reaching peripheral blood from portal blood will be increased from 20% to 30% by this 10% reduction in hepatic extraction, and hence the apparent plasma clearance will fall by more than 50%.

In a recent study using a radioimmunoassay, an oral dose of cholic acid resulted in higher plasma concentrations in cirrhotic patients than in control subjects, particularly when there was portal-systemic shunting. The oral clearance is sensitive to the effect of portal-systemic shunting of blood, but the relative importance of impaired hepatocellular function and intrahepatic shunting of blood cannot easily be distinguished.

Thus the results of this study of bile acid clearances after both oral and intravenous administration may explain the sensitivity of serum bile acid estimations, and have implications for the dosage and route of administration of drugs in patients with chronic liver disease.

ITG was in receipt of an MRC Training Fellowship. The work was supported by the Special Trustees of St. Thomas' Hospital.

References